{
  "source": "PA-Med-Nec-Kevzara.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2199-13\nProgram Prior Authorization/Medical Necessity\nMedication Kevzara® (sarilumab) Injection\nP&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 11/2022, 1/2023, 4/2023, 7/2023,\n2/2024, 8/2024, 10/2024, 4/2025, 6/2025\nEffective Date 9/1/2025\n1. Background:\nKevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of\nadult patients with moderately to severely active rheumatoid arthritis who have had an\ninadequate response or intolerance to one or more disease-modifying antirheumatic drugs\n(DMARDs) 1. Examples of DMARDs commonly used in the treatment of rheumatoid arthritis\ninclude methotrexate, leflunomide, and sulfasalazine.2,3 Kevzara is also indicated for the\ntreatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate\nresponse to corticosteroids or who cannot tolerate corticosteroid taper and for the treatment of\npatients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA).\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Kevzara will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. One of the following:\na. History of failure to a 3 month trial of one non-biologic disease\nmodifying anti-rheumatic drug (DMARD) [e.g., methotrexate,\nleflunomide, sulfasalazine, hydroxychloroquine] at maximally\nindicated doses, unless contraindicated or clinically significant\nadverse effects are experienced (document drug, date, and duration of\ntrial)b\n-OR-\nb. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of rheumatoid arthritis as\n© 2025 UnitedHealthcare Services, Inc.\n1\ndocumented by claims history or submission of medical records\n(Document drug, date, and duration of therapy) [e.g., adalimumab,\nCi",
    "t of rheumatoid arthritis as\n© 2025 UnitedHealthcare Services, Inc.\n1\ndocumented by claims history or submission of medical records\n(Document drug, date, and duration of therapy) [e.g., adalimumab,\nCimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib),\nOrencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab),\nXeljanz/Xeljanz XR (tofacitinib)]\n-AND-\nii. History of failure, contraindication, or intolerance to two of the following\npreferred products (Document drug, date, and duration of trial):\na. One of the preferred adalimumab productsc\nb. Cimzia (certolizumab)\nc. Enbrel (etanercept)\nd. Rinvoq (upadacitinib)\ne. Simponi (golimumab)\nf. Xeljanz/Xeljanz XR (tofacitinib)\n-AND-\niii. History of failure, contraindication, or intolerance to both of the\nfollowing preferred products (Document drug, date, and duration of\ntrial):\na. Actemra (tocilizumab) or Tyenne (tocilizumab-aazg)\nb. Orencia (abatacept)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Kevzara therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nthe prescriber’s office, or any form of assistance from the Sanofi and\nRegeneron sponsored KevzaraConnect® (e.g., sample card which can\nbe redeemed at a pharmacy for a free supply of medication) as a\nmeans to establish as a current user of Kevzara*\n-AND-\n(3) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form o",
    " with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Sanofi and Regeneron sponsored KevzaraConnect® shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kevzara will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\nB. Polymyalgia Rheumatica (PMR)\n1. Initial Authorization\na. Kevzara will be approved based on all of the following criteria:\n(1) Diagnosis of polymyalgia rheumatica (PMR)\n-AND-\n(2) Patient has had an inadequate response to corticosteroids or cannot tolerate\ncorticosteroid taper^\n-AND-\n(3) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n© 2025 UnitedHealthcare Services, Inc.\n3\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kevzara will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), ",
    "mbination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\nC. Polyarticular Juvenile Idiopathic Arthritis (pJIA)\n1. Initial Authorization\na. Kevzara will be approved based on all of the following criteria:\n(1) Diagnosis of active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kevzara will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\n© 2025 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\nc For a list of preferred products please reference drug coverage tools.\n^Tried/failed alternative(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medica",
    "ve(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Kevzara [package insert]. Bridgewater, NJ: Sanofi-Aventis.; February 2023.\n2. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical\npractice guidelines based on published evidence and expert opinions. Joint Bone Spine\n2006;73(4):388-95.\n3. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline\nfor the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.\n2016;68(1):1-26.\nProgram Prior Authorization/Medical Necessity – Kevzara (sarilumab)\nChange Control\n5/2020 New program.\n5/2021 Annual review. Removed prescriber requirement from reauthorization\ncriteria.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting current therapy with Kevzara in order to bypass\nstep if claim history not available.\n12/2021 Updated conventional DMARD bypass language for rheumatoid\narthritis with no change to clinical intent. Updated CT/KY footnote.\n11/2022 Added Enbrel as a preferred product step option. Added Enbrel as an\nexample where appropriate. Added Mississippi to state mandate\nfootnote.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\nAdded coverage criteria for polymyalgia rheumatica. Added Rinvoq as\nan exam",
    "alimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\nAdded coverage criteria for polymyalgia rheumatica. Added Rinvoq as\nan example where appropriate. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n5\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n2/2024 Removed Olumiant as a preferred product for RA. Updated state\nmandate footnote to 30-day trial for Connecticut.\n8/2024 Added clinical coverage criteria for pJIA. Updated background and\nreference. Alphabetized preferred products and targeted\nimmunomodulator examples with no change to intent.\n10/2024 Updated RA step requirement noting Adalimumab-adaz (unbranded\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote.\n4/2025 Removed examples for adalimumab step therapy. Added the footnote\n“For a list of preferred products please reference drug coverage tools.”\n6/2025 Added “Actemra or Tyenne” to step criteria where applicable.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}